Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.
about
Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remissionAssociation between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicityCancer immunoediting from immune surveillance to immune escapeActivity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.Immunomodulatory drugs in myelodysplastic syndromes.Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumorsClinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDSDNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).Erythropoietin receptor signaling is membrane raft dependent.Vascular endothelial growth factor and its receptors in multiple myeloma.Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasiaIdentification of a risk dependent microRNA expression signature in myelodysplastic syndromes.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Does Chemotherapy Change Expression of VEGF A&C and MVD in Acute Myeloid Leukemia?Contribution of bone microenvironment to leukemogenesis and leukemia progression.The role of VEGF in normal and neoplastic hematopoiesis.Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes.Further activation of FLT3 mutants by FLT3 ligandOpportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.Biology of BM failure syndromes: role of microenvironment and niches.Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications.Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.Embryonic Stem Cell (ES)-Specific Enhancers Specify the Expression Potential of ES Genes in Cancer.Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.Emerging drugs for the treatment of myelodysplastic syndrome.First Evidence that Sika Deer (Cervus nippon) Velvet Antler Extract Suppresses Migration of Human Prostate Cancer Cells.Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK functionSignificance of wine and resveratrol in cardiovascular disease: French paradox revisitedTargeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence.The evolving role of lenalidomide in the treatment of hematologic malignancies.Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.
P2860
Q21245489-81BFB42C-9C72-44C5-A9F6-10D12FDF964BQ24626427-9AE8299C-B996-4251-921C-9F570D3E82B6Q24655415-064B08E0-A5B9-4AE2-9408-710413CCB298Q33365126-0B507218-87F8-4306-84E5-41D0B1B4CC8CQ33371622-52B9F362-809C-429F-95C6-D2351A33C927Q33373984-E6FDB6C6-7384-45CA-B019-5C506D2D5DF3Q33416674-BD0097B4-A4D9-40AB-91D0-140BCECEA5CEQ33513801-58E0012A-6F07-456D-85EE-760BACAF3DC3Q33733541-4589746B-F2B5-4CC2-909A-346C9503E016Q34129693-2B801DA4-0165-4372-8459-24BC68DA0E16Q34235219-21C67278-49F9-489E-9B0E-72A34CD8E2F5Q34265556-F0D4536C-4D62-4DE6-B31A-26A8BF8A49FAQ34558522-58ADE607-3D2B-41FC-A77C-A88960A94287Q34955338-5A448C20-AEA0-4E32-B9B2-34EABB38981EQ35001132-29B229BC-E063-4D60-9008-9716F027A7C9Q35009275-6C3573C4-A799-48E6-92E1-E1B04C88280BQ35037058-87F4117E-B526-469A-ADD3-118B839947F0Q35052515-D64028C7-D611-49AB-8FA2-2FF8511F161FQ35104368-1F6232FD-6811-46F7-9C38-A3B3F4AD7399Q35163307-19C3A1E3-FF16-4C36-9702-7BA8F396F664Q35186892-967E9FA1-B558-4B54-8AC2-75EEB5DBD456Q35568527-9A4E3D2E-C08F-47FA-BB4F-762199EB57EAQ35854951-970226FA-87EB-40E2-99E6-6A6051D181F8Q35900957-88DD6C94-ECDF-4BB7-9552-2DFAE46A4C40Q35926106-76F36FC0-4F76-426E-B4ED-BE8CFEFB664FQ36194610-5E0DD846-194A-4E1A-9F7D-8F1F94C41312Q36219655-F41AE108-0E45-46A3-9350-41CCAFD217FBQ36325346-33992791-62CD-4B7F-86A5-8F29D9F28052Q36330960-56AEB80A-CD4A-4598-8FEA-5A6835C3E7A8Q36429603-5342AE21-580B-4862-87ED-FE609EB624BBQ36498379-E4BF5B81-CB7A-47E8-89D9-2BC76CF54C35Q36511645-E22E75F5-CCD5-4CEB-8E40-F1DFF2BC1A44Q36547805-27B4B92C-3B70-4DB2-9542-7859EB2AE9A2Q36612675-56A629DE-0DDB-4046-8905-A942D6E47211Q36617092-5AF4EA92-ACC5-469A-B047-F8C99F8D4C0DQ36739807-9164799A-3A85-4AEA-9537-CA83E90C97C4Q36764907-EE79E3D2-64E9-4C0C-9FBB-A9C8CEEA767AQ36876853-1554653E-CFF1-4097-A416-46127AE766EDQ36976217-5F9DCB52-E74B-42AC-BAFD-5DDD7B6AB9D2Q36988558-06CC3E31-02C5-4264-AAA0-12A4E6C5D791
P2860
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Vascular endothelial cell grow ...... in myelodysplastic syndromes.
@ast
Vascular endothelial cell grow ...... in myelodysplastic syndromes.
@en
type
label
Vascular endothelial cell grow ...... in myelodysplastic syndromes.
@ast
Vascular endothelial cell grow ...... in myelodysplastic syndromes.
@en
prefLabel
Vascular endothelial cell grow ...... in myelodysplastic syndromes.
@ast
Vascular endothelial cell grow ...... in myelodysplastic syndromes.
@en
P2093
P356
P1433
P1476
Vascular endothelial cell grow ...... n in myelodysplastic syndromes
@en
P2093
B Glinsmann-Gibson
T M Grogan
W T Bellamy
Y Frutiger
P304
P356
10.1182/BLOOD.V97.5.1427
P407
P50
P577
2001-03-01T00:00:00Z